1.Holden, C. ‘Behavioral’ addictions: do they exist? Science. 2001;294:980–982.
2.Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
3.Grant, JE, Potenza, MN. Pathological gambling and other behavioral addictions. In: Frances, RJ, Miller, SI, Mack, AH, eds. Clinical Textbook of Addictive Disorders. 3rd ed. New York: Guildford Press; 2005:303–320.
4.Blanco, C, Moreyra, P, Nunes, EV, Saiz-Ruiz, J, Ibanez, A. Pathological gambling: addiction or compulsion? Semin Clin Neuropsychiatry. 2001;6:167–176.
5.Potenza, MN. Should addictive disorders include non-substance-related conditions? Addiction. 2006;101(suppl 1):142–151.
6.Chambers, RA, Potenza, MN. Neurodevelopment, impulsivity, and adolescent gambling. J Gambl Stud. 2003;19:53–84.
7.Potenza, MN, Kosten, TR, Rounsaville, BJ. Pathological gambling. JAMA. 2001;286:141–144.
8.Crockford, DN, el-Guebaly, N. Psychiatric comorbidity in pathological gambling: a critical review. Can J Psychiatry. 1998;43:43–50.
9.Petry, NM, Stinson, FS, Grant, BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66:564–574.
10.McCormick, RA, Russo, AM, Ramirez, LF, Taber, JI. Affective disorders among pathological gamblers seeking treatment. Am J Psychiatry. 1984;141:215–218.
11.Cunningham-Williams, RM, Cottler, LB, Compton, WM III, Spitznagel, EL. Taking chances: Problem gamblers and mental health disorders-results from the St. Louis Epidemiologic Catchment Area study. Am J Pub Health. 1998;88:1093–1096.
12.Spunt, B, Lesieur, H, Hunt, D, Cahill, L. Gambling among methadone patients. Int J Addict. 1995;30:929–962.
13.Grant, JE, Kim, SW. Clinical characteristics and associated psychopathology of 22 patients with kleptomania. Compr Psychiatry. 2002;43:378–384.
14.McElroy, SL, Pope, HG, Hudson, JI, Keck, PE, White, KL. Kleptomania: a report of 20 cases. Am J Psychiatry. 1991;148:652–657.
15.Christenson, GA, Faber, RJ, de Zwaan, M, et al.Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry. 1994;55:5–11.
16.Schlosser, S, Black, DW, Repertinger, S, Freet, D. Compulsive buying: demography, phenomenology, and comorbidity in 46 subjects. Gen Hosp Psychiatry. 1994;16:205–212.
17.Potenza, MN. The neurobiology of pathological gambling. Semin Clin Neuropsychiatry. 2001;6:217–226.
18.Benkelfat, C, Murphy, DL, Hill, JL, George, DT, Nutt, D, Linnoila, M. Ethanollike properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry. 1991;48:383.
19.Kalivas, PW, Volkow, ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403–1413.
20.Bergh, C, Eklund, T, Sodersten, P, Nordin, C. Altered dopamine function in pathological gambling. Psychol Med. 1997;27:473–475.
21.Blum, K, Cull, JG, Braverman, ER, Comings, DE. Reward deficiency syndrome. Am Scientist. 1996;84:132–145.
22.Nestler, E, Aghajanian, GK. Molecular and cellular basis of addiction. Science. 1997;278:58–62.
23.Chambers, RA, Taylor, JR, Potenza, MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry. 2003;160:1041–1052.
24.Loba, P, Stewart, SH, Klein, RM, Blackburn, JR. Manipulations of the features of standard video lottery terminal (VLT) games: effects in pathological and non-pathological gamblers. J Gambl Stud. 2001;17:297–320.
25.Zack, M, Poulos, CX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacol. 2004;29:195–207.
26.Dackis, C, O'Brien, C. Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci. 2005;8:1431–1436.
27.Grant, JE, Potenza, MN, Hollander, E, et al.A multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163:303–312.
28.Grant, JE, Kim, SW. An open label study of naltrexone in the treatment of kleptomania. J Clin Psychiatry. 2002;63:349–356.
29.Kim, SW, Grant, JE, Adson, D, Shin, YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914–921.
30.Volpicelli, JR, Alterman, AI, Hayashida, M, O'Brien, CP. Naltrexone in the treatment of alcohol dependence Arch Gen Psychiatry. 1992;49:876–880.
31.Mason, BJ, Salvato, FR, Williams, LD, Ritvo, EC, Cutler, RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719–724.
32.Schmitt, LH, Harrison, GA, Spargo, RM. Variation in epinephrine and cortisol excretion rates associated with behavior in an Australian Aboriginal community. Am J Phys Anthropol. 1998;106:249–253.
33.Ramirez, LF, McCormick, RA, Lowy, MT. Plasma cortisol and depression in pathological gamblers. Br J Psychiatry. 1988;153:684–686.
34.Roy, A, Adinoff, B, Roehrich, L, et al.Pathological gambling. A psychobiological study. Arch Gen Psychiatry. 1988;45:369–373.
35.Meyer, G, Hauffa, BP, Schedlowski, M, Pawlak, C, Stadler, MA, Exton, MS. Casino gambling increases heart rate and salivary cortisol in regular gamblers. Biol Psychiatry. 2000;48:948–953.
36.Krueger, THC, Schedlowski, M, Meyer, G. Cortisol and heart rate measures during casino gambling in relation to impulsivity. Neuropsychobiology. 2005;52:206–211.
37.Meyer, G, Schwertfeger, J, Exton, MS, et al.Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology. 2004;29:1272–1280.
38.Potenza, MN, Steinberg, MA, Skudlarski, P, et al.Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry. 2003;60:828–836.
39.Potenza, MN, Leung, HC, Blumberg, HP, et al.An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry. 2003;160:1990–1994.
40.Reuter, J, Raedler, T, Rose, M, Hand, I, Glascher, J, Buchel, C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci. 2005;8:147–148.
41.London, ED, Ernst, M, Grant, S, Bonson, K, Weinstein, A. Orbitofrontal cortex and human drug abuse: functional imaging. Cereb Cortex. 2000;10:334–342.
42.Bechara, A. Risky business: emotion, decision-making, and addiction. J Gambl Stud. 2003;19:23–51.
43.Lim, KO, Choi, SJ, Pomara, N, Wolkin, A, Rotrosen, JP. Reduced frontal white matter integrity in cocaine dependence: a controlled diffusion tensor imaging study. Biol Psychiatry. 2002;51:890–895.
44.Grant, JE, Correia, S, Brennan-Krohn, T. White matter integrity in kleptomania: a pilot study. Psychiatry Res Neuroimaging. 2006;147:233–237. Epub 2006 Sep 7.
45.Hollander, E, Pallanti, S, Baldini Rossi, N, Sood, E, Baker, BR, Buchsbaum, MS. Imaging monetary reward in pathological gamblers. World J Biol Psychiatry. 2005;6:113–120.
46.Crockford, DN, Goodyear, B, Edwards, J, Quickfall, J, el-Guebaly, N. Cue-induced brain activity in pathological gamblers. Biol Psychiatry. 2005;58:787–795.
47.Cavedini, P, Riboldi, G, Keller, R, D'Annucci, A, Bellodi, L. Frontal lobe dysfunction in pathological gambling patients. Biol Psychiatry. 2002;51:334–341.
48.Petry, NM. Pathological Gambling: Etiology, Comorbidity, and Treatment. Washington, DC: American Psychological Association; 2005.
49.Rugle, L, Melamed, L. Neuropsychological assessment of attention problems in pathological gamblers. J Nerv Ment Dis. 1993;181:107–112.
50.Specker, SM, Carlson, GA, Christenson, GA, Marcotte, M. Impulse control disorders and attention deficit disorder in pathological gamblers. Ann Clin Psychiatry. 1995;7:175–179.
51.Diskin, KM, Hodgins, DC. Narrowing of attention and dissociation in pathological video lottery gamblers. J Gambl Stud. 2000;16:461–467.
52.Goudriaan, AE, Oosterlaan, J, de Beurs, E, van den Brink, W. Neurocognitive functions in pathological gambling: a comparison with alcohol dependence, Tourette syndrome and normal controls. Addiction. 2006;101:534–547
53.Kertzman, S, Lowengrub, K, Aizer, A, Ben Nahum, Z, Kotler, M, Dannon, PN. Stroop performance in pathological gamblers. Psychiatry Res. 2006;142:1–10.
54.Grant, JE, Odlaug, BL, Wozniak, JR. Neuropsychological functioning in kleptomania. Behav Res Ther. 2006 Sep 26: [Epub ahead of print].
55.Shah, KR, Potenza, MN, Eisen, SA. Biological basis for pathological gambling. In Grant, JE, Potenza, MN, eds. Pathological Gambling: A Clinical Guide to Treatment. Washington DC: American Psychiatric Publishing, Inc; 2004:127–142.
56.Potenza, MN, Xian, H, Shah, K, Scherrer, JF, Eisen, SA. Shared genetic contributions to pathological gambling and major depression in men. Arch Gen Psychiatry. 2005;62:1015–1021.
57.Comings, DE, Rosenthal, RJ, Lesieur, HR, et al.A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics. 1996;6:223–234.
58.Comings, DE, Gade, R, Wu, S, et al.Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry. 1997;2:44–56.
59.Comings, DE, Gonzalez, N, Wu, S, et al.Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet. 1999;88:358–368.
60.Perez de Castro, I, Ibanez, A, Torres, P, Saiz-Ruiz, J, Fernandez-Piqueras, J. Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics. 1997;7:345–348.
61.O'Brien, CP, McKay, J. Pharmacological treatments for substance use disorders. In: Nathan, PE, Gorman, JM, eds. A Guide to Treatments that Work. 2nd ed. New York, NY: Oxford University Press: 2002:125–156.
62.Grant, JE, Potenza, MN. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry. 2004;16:27–34.
63.Oslin, DW, Berrettini, W, Kranzler, HR, et al.A functional polymorphism of the muopioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546–1552.
64.Potenza, MN. Impulse control disorders and co-occurring disorders: dual diagnosis considerations. Journal of Dual Diagnosis. In press.
65.Hollander, E, Kaplan, A, Pallanti, S. Pharmacological treatments. In: Grant, JE, Potenza, MN. Pathological Gambling: A Clinical Guide to Treatment. Washington DC: American Psychiatric Publishing, Inc. 2004:189–206.
66.Hollander, E, DeCaria, CM, Finkell, JN, Begaz, T, Wong, CM, Cartwright, C. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry. 2000;47:813–817.
67.Hollander, E, Pallanti, S, Allen, A, Sood, E, Baldini Rossi, N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162:137–146.
68.Grant, JE, Potenza, MN. Escitalopram in the treatment of pathological gambling with co-occurring anxiety: An open-label study with double-blind discontinuation. Int Clin Psychopharmacol. 2006;21:203–209.
69.Black, DW. An open-label trial of bupropion in the treatment of pathologic gambling. J Clin Psychopharmacol. 2004;24:108–110.
70.Stein, DJ, Lochner, C. Obsessive compulsive spectrum disorders: a multidimensional approach. Psychiatr Clin N Am. 2006;29:343–351.